Canadian Cancer Trials Group - Tumour Bank
Logged in as: Public
Location: Home - Disease Sites - - PR12

PR12 Details
Status: Closed 
Activation Date: 2008MAR03
Closing Date: 2009NOV12
Phase: III 

Description: Phase III Study of Neoadjuvant Docetaxel And Androgen Suppression Plus Radiation Therapy Versus Androgen Suppression Alone Plus Radiation Therapy For High-Risk Localized Adenocarcinoma Of The Prostate (DART) 

Eligibility: Patients with histologically proven, localized (NO, M0) adenocarcinoma of the prostate with adverse prognostic features which are considered to be high risk for recurrence based on the presence of at least one of the following features: T stage > or = to 3a, Gleason Score > or = 8 or presenting PSA>20 

Objective: The primary objective is to compare disease free survival rates in men treated with androgen suppression therapy and radiation therapy followed by androgen suppression therapy with or without neoadjuvant docetaxel. Secondary objectives include overall survival, degree of PSA suppression prior to radiation therapy and Quality of Life. 

Participation: Open to member centres 

Lay Description: This study looks at men with prostate cancer that are at high risk of the disease returning. The purpose of this study is to compare the effects, on prostate cancer, of a chemotherapy drug (Docetaxel) given with the standard treatment compared to the standard treatment alone. The standard treatment for this cancer is hormone therapy and local radiation therapy. 

Primary Publication Show

Other Publications Show

Inventory
Hide Tissue Samples
Hide TMA Samples
Hide Fluid Samples

© 2024 Canadian Cancer Trials Group.